503A Compounded Peptides: What the FDA's Review Actually Means

Section 503A of the Federal Food, Drug, and Cosmetic Act creates a carve-out. State-licensed compounding pharmacies can prepare patient-specific medications without going through the full FDA new-drug-approval process — which costs hundreds of millions of dollars and takes years — provided the bulk drug substances they use meet one of three conditions:

• They appear on an eligible list (the 503A bulk substances list)
• They have a USP monograph
• They're components of already-approved drugs

Many peptides don't have USP monographs. They're not components of approved commercial drugs. For them, the relevant pathway is the FDA's bulk substances nomination list — a living document the agency updates as it evaluates nominations submitted by pharmacies, physicians, and manufacturers.

That document — not a DEA schedule, not a press release, not a Telegram channel admin's interpretation — is what determines whether a licensed 503A compounding pharmacy can legally compound a given peptide.

The FDA sorts nominated bulk substances into practical categories. Three states matter:

Category 1 — Eligible while under evaluation. The FDA has accepted the nomination and is reviewing it. The substance hasn't received a negative determination. Critically, this is not a safety endorsement — it's the absence of a negative finding. A physician can prescribe a Category 1 compound from a licensed 503A pharmacy within the framework. Substances can sit in this status for years while the agency works through its review queue.

Category 2 — Restricted, significant safety concerns identified. When the FDA flags a substance for safety risks or insufficient data, it moves here. Technically, category determinations are guidance rather than binding Administrative Procedure Act regulation — the formal objection and petition pathways remain open. Practically, most reputable 503A pharmacies treat Category 2 as effectively binding. Compounding a formally flagged substance creates regulatory exposure, worsens liability if an adverse event occurs, and strains relationships with the agency that matter for ongoing operations. Thymosin Alpha-1 went through this — formal objections and evidence submissions moved the FDA to revisit its determination. The process is real.

Removed or reclassified. Substances withdrawn for procedural reasons, additional evidence, or formal petition outcomes. This category has been administered inconsistently over time, which matters if you're trying to interpret older regulatory news.

One nuance worth understanding: a PCAC (Pharmacy Compounding Advisory Committee) recommendation is not a binding rule. The committee advises. Formal rulemaking — the step that actually changes what pharmacies can compound — can take twelve months or more even after a favorable advisory vote. Headlines saying a peptide is "cleared" after a PCAC meeting overstate where things stand.

The distinction that gets glossed over in almost every consumer-facing piece on this topic.

503A governs state-licensed compounding pharmacies preparing patient-specific prescriptions. This is what your telehealth provider uses. The pharmacy compounds against a specific prescription from a specific licensed physician for a specific patient. Subject to state pharmacy board oversight and USP Chapter 797 sterility standards for sterile preparations.

503B governs FDA-registered outsourcing facilities compounding for healthcare facilities — hospitals, clinics — without patient-specific prescriptions, under cGMP manufacturing standards. Think large-scale batch production for surgical centers.

The bulk substances lists for 503A and 503B are different. An action on one list doesn't automatically affect the other. When you see a headline about peptide compounding, the first filter is: which pathway is this about? Most physician-prescribed peptide therapy moves through the 503A pathway. Most confusion in the space involves conflating the two.

On April 23, 2026, twelve peptides were effectively removed from the FDA's Category 2 restricted list following a February 2026 announcement by HHS Secretary Kennedy. The peptides removed include BPC-157, TB-500, CJC-1295, Ipamorelin, MOTS-c, Epitalon, Semax, Selank, GHK-Cu, KPV, LL-37, and Thymosin Alpha-1.*

This matters. The framing in every credible source on this, including the FDA Law Blog, is that these moves "likely redirected demand from the black market" back toward a regulated framework — the government's own acknowledgment that the 2023 restrictions produced "very, very substandard ingredients" in uncontrolled supply chains. Secretary Kennedy's phrase, not ours.

Here's what the April 2026 action is not:

• It is not FDA approval. Reclassification is a regulatory designation, not a drug-approval determination.
• It is not a green light to compound freely. Seven of these peptides are under active PCAC review July 23–24, 2026. The committee evaluates; it advises; formal 503A eligibility determinations follow.
• It is not permanent. Category placements are living designations. A substance can move in either direction.

The question every patient should ask of any provider: which specific molecules are you working with, and what's their current 503A status? The honest answer involves checking the FDA's bulk drug substances nomination page directly — not a blog post from six months ago.

We operate our formulary against current categorizations. At the time of this writing, three molecules form the core of what we compound for patients: Sermorelin, NAD+, and Glutathione. All three are in Category 1 — eligible while under ongoing FDA evaluation.

Sermorelin is a growth hormone–releasing hormone (GHRH) analogue with a compounding track record that precedes much of the current regulatory framework. Think of GHRH as the foreman who's been locked out of the job site since you turned 30. The crew is still there. The materials are still there. Nobody's been telling them to start work. Sermorelin is designed to address that gap — not adding something foreign, but getting a system you already own to clock back in. It has been through extended FDA evaluation without restriction. A compounded sermorelin preparation is not an FDA-approved drug. A physician prescribing it is making a clinical judgment that the potential benefit for a specific patient warrants the use of a compounded preparation.

NAD+ (nicotinamide adenine dinucleotide) injectable preparations have been available through the compounding framework, subject to ongoing FDA evaluation. The molecule itself is a coenzyme found in every cell — involved in hundreds of enzymatic reactions across energy metabolism, DNA repair signaling, and mitochondrial function. Injectable preparations have been used in clinical settings for decades. The research on NAD+ precursors and cellular health continues to develop; the injectable compounded form carries a different evidence profile than oral supplementation. Evaluation continues.

Glutathione injectable preparations have similarly been available through compounding. The FDA has issued warnings in the context of certain skin-lightening uses — a different market segment from clinical longevity and performance medicine. That regulatory activity doesn't touch the compounding framework for physician-prescribed uses in a clinical context. Evaluation continues.

One line that belongs on every formulary conversation: none of these molecules are permanently shielded. The FDA's review is ongoing. Any substance currently eligible could receive a different determination. We monitor the list, and we update our formulary accordingly.

This is the part the research-chemical sellers don't put on the label.

The molecule in a vial ordered through a Telegram channel might be exactly what it claims to be. The problem is that there's no way to verify it — not for you, and not for the seller. Independent analyses of peptides sourced from online vendors found roughly 38% met basic purity standards.* That's not a scare statistic designed to make you feel bad about choices you've already made. It's a coin flip on something you inject.

The customs data makes the supply-chain concern concrete: U.S. imports of peptides from China nearly doubled in a single year during the period of Category 2 restrictions.* The raw material entering the gray market isn't domestically sourced, isn't tested by anyone with a license on the line, and isn't arriving in sterile conditions. "Research grade" on a Chinese-sourced peptide label means exactly nothing in terms of pharmaceutical-grade manufacturing controls.

The FDA's 503A framework exists to address this gap. A licensed 503A pharmacy is subject to state pharmacy board oversight, compounding standards, and — if it's operating responsibly — USP Chapter 797 sterility requirements for sterile preparations. Chapter 797 isn't a suggestion; it's a 200-page standard that governs everything from clean room classification to beyond-use dating. The physician prescribing is licensed, identifiable, and accountable. The bulk substance sourcing is verified against a Certificate of Analysis from an FDA-registered manufacturer.

"Pharmaceutical-grade" is not a marketing phrase. It's a description of a specific supply chain with specific accountability at each step — sourcing, manufacturing, sterility, dispensing, and physician oversight. The gray market has none of these. The risk profile is not the same.

Secretary Kennedy's own words: the 2023 restrictions "created a black market" producing "very, very substandard ingredients." We're not here to moralize about people who've used research-chemical peptides — most of the people reading this have, and the mechanism interest was legitimate. The point is that "probably fine" is a strange standard to apply to a sterile injectable when the regulated alternative exists.

When a new headline lands, three questions determine whether it matters:

Which molecule? The FDA acts on specific substances. A restriction on BPC-157 tells you nothing about Sermorelin. A reclassification of twelve peptides tells you nothing about the five pending February 2027 PCAC review. Read the FDA's bulk drug substances nomination page directly — it's a PDF on FDA.gov, updated as actions occur — not the summary.

Binding rule or guidance? Category determinations are guidance, not binding APA regulation. The formal objection and petition pathways remain open. A favorable PCAC vote is advisory. Formal eligibility under 503A requires rulemaking that takes months to years beyond the committee meeting. This matters if you're following a specific molecule — "PCAC approved it" and "you can get it compounded" are separated by a significant procedural gap.

503A or 503B? Different pathways, different lists, different standards. Changes to one don't automatically affect the other. Most physician-prescribed peptide therapy moves through 503A. Most regulatory confusion conflates the two.

Several developments are active:

PCAC meeting, July 23–24, 2026. Seven peptides are on the agenda: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon. The committee will evaluate each for section 503A eligibility. Advisory votes are non-binding; formal rulemaking follows. Public comments accepted through FDA docket FDA-2025-N-6895 until July 22, 2026.

Second PCAC meeting, by February 2027. Five additional peptides under review: GHK-Cu, Melanotan II, LL-37, Dihexa acetate, and PEG-MGF.

IND and NDA activity. As specific peptide molecules enter formal US clinical development, the regulatory calculus for compounding changes. An approved drug alters which 503A exemptions apply.

State-level actions. State pharmacy boards don't always move in lockstep with FDA guidance. That creates variation in what's available where — something to understand if you're in a state with a particularly active pharmacy board.

We track all of this. Our formulary reflects current eligible status, not where we wish status was.

We treat the 503A bulk substances list as a living document and maintain our formulary against current categorizations. Every molecule we work with is eligible under the framework at the time of prescribing. Every prescription comes from a licensed physician. Every compound comes from a licensed 503A pharmacy operating under applicable sterility and quality standards.

The intake process — bloodwork first, clinical review before any prescription — isn't a compliance formality. It's what physician oversight actually means. We don't prescribe into the dark. We know what your labs say before we recommend anything, and we know what you're getting when we prescribe it.

Whether any treatment is appropriate for you specifically is a clinical decision that belongs to a licensed provider who has reviewed your history, your goals, and your current numbers. You can't optimize what you refuse to measure. So measure first.

Book a free consultation →